Breaking News on Contract Research, Manufacturing & Clinical Trials

Hot Topics > Consolidation

Consolidation

The pharmaceutical industry seems besieged on all sides by declining R&D productivity, expiring patents and relentless downward pricing pressure. One effect of this onslaught has been an upsurge in the level of consolidation as industry players attempt to cut costs, expand research pipelines and lengthen geographic reach.

B-MS outsources manufacture of products in 5 year deal

08-Sep-2009 - Bristol-Myers Squibb (B-MS) has outsourced the manufacture of some of its products to Sigma Pharmaceuticals, an Australia-based company that also bought a facility from the big pharma for A$60m ($51.7m)....

Cloud Packaging meets shorter run trend with Toll takeover

07-Sep-2009 - Cloud Packaging Solutions has said the acquisition of Toll Packaging will boost its ability to meet the increased demand for shorter packing runs triggered by the current global economic crisis.

Averion plans going private to cut outgoings

07-Sep-2009 - CRO Averion is planning to become a private company to reduce expenditure on auditor fees, which could realise savings of $805,000 (€561,000), and allow management to better focus on long-term goals.

PharmaForm streamlined as Akela Pharma restructures

04-Sep-2009 - US contract services firm PharmaForm has cut its workforce to 65 employees in a restructuring plan that parent company Akela Pharma said optimises its client support infrastructure.

JLL says Lonza’s $460m Patheon bid is “hostile”

04-Sep-2009 - US investment group JLL has described Lonza’s rival offer for Patheon as “a hostile attempt to adversely impact [the Canadian contractor’s] competitive position.”

Evotec buys in India to quicken drug development services

04-Sep-2009 - By acquiring a stake in India-based RSIPL Evotec believes it can offer clients quicker drug development services, an important aspect of coping with attrition, because larger teams of chemists are...

MDS trying to sell Pharma Services business

03-Sep-2009 - Facing “unparalleled” challenges MDS is seeking a buyer for its Pharma Services division, and claims to have begun discussions with two interested parties, to allow it to focus on its...

Californian budget deficit poses “real risk” to biotech investment

02-Sep-2009 - The Californian budget deficit presents a “real risk to future biotech investments”, according to the CEO of BayBio who explained to how the industry now has a difficult relationship with...

Summit sells Dextra services division

02-Sep-2009 - Summit has sold Dextra, its analytical and manufacturing services division, to NZP but believes operating the contract business has been beneficial to its industry standing and R&D capabilities.

News in brief

Clinilabs adds Asian cost efficiencies with H&J deal

02-Sep-2009 - US CRO Clinilabs hopes its new link up with Chinese counterpart H&J CRO International will allow it to “manage early phase and specialty studies in the US, while offering our...

SBS looks to buy after making profit

26-Aug-2009 - Source BioScience (SBS) is eyeing acquisitions and investments in technology after it posted a profit in the first six months of 2009, overturning a loss in the same period of...

Encorium plans liquidation if subsidiary sold

25-Aug-2009 - Encorium plans to liquidate if it can negotiate the sale of its Finland-based business, which could happen in the fourth quarter.

Will Lonza's $460m Patheon offer trigger bidding war?

24-Aug-2009 - Canadian contractor Patheon has welcomed the $460m (€321m) takeover offer from Switzerland's Lonza that could, according to some observers, spark a bidding war with rival suitor, US group JLL Patheon...

News in brief

Lonza offer a "significant improvment" on JLL bid, says chair of Patheon's special committee

21-Aug-2009 - Swiss firm Lonza has tabled a $3.55 per share bid for Canadian CMO Patheon, bettering the $2 per share offered by investment group JLL.

Millipore buys BioAnaLab to expand in EU

11-Aug-2009 - Millipore has expanded its European biotech services business by acquiring BioAnaLab, a UK-based company that provides analysis of biologics and vaccines.

Phase Forward's income drops in Q2

28-Jul-2009 - Phase Forward’s GAAP net income fell by 41 per cent in Q2 despite an increase in revenues, as rising operating costs hit the company.

Alcan talks still on in wake of Bemis deal, says Amcor

20-Jul-2009 -  Australian group Amcor has confirmed that talks about a takeover of Alcan’s pharmaceutical packaging business are still ongoing but says that no binding agreement has yet been reached.

Sepha shows off BlisterScan in Japan

06-Jul-2009 -  Northern Irish pack testing specialist Sepha has moved forward with plans to enter the Japanese market, showcasing its BlisterScan platform at Interphex Japan in Tokyo last week.

NERI and ProMedica team up to offer Ph I-IV research solutions

28-May-2009 -  US CROs NERI and the ProMedica Clinical Research Center have teamed up to offer comprehensive Phase I-IV trial services to the drug industry.

Fate seeks partners to be iPS Catalyst

26-May-2009 -  There has been “tremendous interest” in Fate Therapeutics’ Catalyst programme, which gives access to induced iPS cell technology as part of collaborative relationship between numerous companies.

PDI’s losses mount in Q1

13-May-2009 -  PDI posted a larger operating loss in Q1 2009 than in the previous year, with the company blaming the decline on the expiration, termination and postponement of contracts.

Siro ClinPharm and ACT team up on oncology

20-Apr-2009 -  Indian CRO Siro ClinPharm is teaming up with New Jersey based pharma services firm Advanced Clinical Trial Solutions (ACT) to strengthen its position in the US cancer trial sector.

GVK - Excel alliance reaches from India to China

16-Apr-2009 -  Companies seeking research services in India and China will now be able to use a single contact following an alliance between GVK BIO and Excel, which the companies claim is...

CROs pursue international expansion

09-Apr-2009 -  The past few days have seen a string of announcements from contract research organisations (CROs) which indicate that their appetite for international expansion and development remains unsated. 

CardioNet breaks into CRO sector with Biotel buy

08-Apr-2009 -  US company CardioNet, which specialises in mobile cardiac monitoring devices, has made a foray into the contract research sector with a $14m offer to acquire cardiovascular research firm Biotel.

Key Industry Events

 

Access all events listing

Our events, Events from partners...